PGUS-AD1

PGUS-AD1 is an investigational stem cell therapy being developed by PrimeGen Biotech for the treatment of atopic dermatitis. PrimeGen Biotech is a California-based regenerative medicine company that focuses on the development of stem cell-based therapeutics and exosome technologies. PGUS-AD1 is intended to address the inflammatory and immune-mediated components of atopic dermatitis. While the company's 2021 pipeline documentation lists the candidate in Phase 3 development, there is currently no record of associated Phase 3 clinical trials in public databases such as ClinicalTrials.gov, which may indicate that the program is in a pre-clinical stage or that trials are being conducted outside of major regulatory oversight.